The case for conducting a randomized clinical trial to assess the efficacy of a single dose of prophylactic HPV vaccines among adolescents

Journal of the National Cancer Institute

Volumn 107, Issue 3, 2015, Pages

  Kreimer, Aimeé R ^a   Sherman, Mark E ^a   Sahasrabuddhe, Vikrant V ^a,b   Safaeian, Mahboobeh ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ANTIBODY TITER; ENZYME LINKED IMMUNOSORBENT ASSAY; HERD IMMUNITY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; NOTE; PAPILLOMAVIRUS INFECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); UTERINE CERVIX CANCER; VACCINE FAILURE; ADOLESCENT; COMPARATIVE STUDY; COMPLICATION; COST BENEFIT ANALYSIS; DOSE RESPONSE; FEMALE; IMMUNIZATION; METHODOLOGY; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; UNITED STATES; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

ADOLESCENT; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; UNITED STATES; UTERINE CERVICAL NEOPLASMS;

EID: 84930394202     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju436     Document Type: Note

References (28)

1. de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048-1056.
2. Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30(Suppl 5):F12-F23.
3. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301-314.
4. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915-1927.
5. Kreimer AR, Rodriguez AC, Hildesheim A, et al. Proof-ofprinciple evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst. 2011;103(19):1444-1451.
6. Safaeian M, Porras C, Pan Y, et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila). 2013;6(11):1242-1250.
7. Lamontagne D, Mugisha E, Pan Y, et al. Immunogenicity of bivalent HPV vaccine among partially vaccinated young adolescent girls in Uganda (under review).
8. Dobson SR, McNeil S, Dionne M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA. 2013;309(17):1793-1802.
9. Romanowski B, Schwarz TF, Ferguson LM, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin. 2011;7(12):1374-1386.
10. Lyseng-Williamson KA. Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine (Cervarix): A Guide to Its Two-Dose Schedule in Girls Aged 9-14 Years in the EU. Paediatr Drugs. 2014; In press.
11. PAHO. Technical Advisory Group on Vaccine-preventable Diseases: "Vaccination: a shared responsibility". http://www. paho.org/hq/index.php?option=com-docman&task=doc-download&gid=22423&Itemid=270. Accessed January 2, 2015.
12. WHO. Summary of the SAGE April 2014 meeting. http://www. who.int/immunization/sage/meetings/2014/april/report-summary-april-2014/en/. Accessed January 2, 2015.
13. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-2917.
14. Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol. 2010;10(11):787-796.
15. Safaeian M, Porras C, Pan Y, et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res. 2013;6(11):1242-1250.
16. Safaeian M, Hildesheim A, Pan Y, et al. Abstract PH.OA02.04: HPV16 antibody avidity following one and two doses of HPV16/18 vaccine: results from the Costa Rica Vaccine Trial (CVT). 29th International Papillomavirus Conference and Public Health & Clinical Workshops. August 21-25, 2014. Seattle, WA.
17. Joura, E. Efficacy and immunogenicity of a novel 9-valent HPV L1 virus-like particle vaccine in 16-to 26-year-old women, EUROGIN 2013, November 5, 2013. Florence, Italy.
18. Einstein M, Baron M, Levin MJ, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: Follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccin. 2011;7(12):1343-1358.
19. Herweijer E, Leval A, Ploner A, et al. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma. JAMA. 2014;311(6):597-603.
20. Crowe E, Pandeya N, Brotherton JM, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ. 2014;348:g1458.
21. Gertig DM, Brotherton JM, Budd AC, et al. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med. 2013;11:227.
22. Herrero R, Wacholder S, Rodriguez AC, et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov. 2011;1(5):408-419.
23. Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA. 2007;298(7):743-753.
24. Naud PS, Roteli-Martins CM, De Carvalho NS, et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: Hum Vaccin Immunother. 2014;10(8):2147-2162. doi:10.4161/hv.29532. PMID:25424918.
25. Ferris D, Samakoses R, Block SL, et al. Long-term Study of a Quadrivalent Human Papillomavirus Vaccine. Pediatrics. 2014;134(3):e657-e665.
26. International Agency for Research on Cancer. Primary Endpoints for Prophylactic HPV Vaccine Trials. Lyon, France: International Agency for Research on Cancer (IARC Working Group Reports, No. 7). IARC HPV Working Group (2014) 2014 (E-pub).
27. Wheeler CM, Hunt WC, Cuzick J, et al. A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination. Int J Cancer. 2012;132(1):198-207.
28. CDC. Human Papillomavirus Vaccination Coverage Among Adolescent Girls, 2007-2012, and Postlicensure Vaccine Safety Monitoring, 2006-2013; United States. MMWR. 2013;62(29);591-595.